Skip to content

Study · Randomized controlled trial · n = 124 · 2015

10 results

Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial).

Lind M, Hirsch IB, Tuomilehto J, Dahlqvist S, Ahrén B, Torffvit O, Attvall S, Ekelund M, Filipsson K, Tengmark BO, Sjöberg S, Pehrsson NG

BMJ (Clinical research ed.)28 Oct 2015Cited by 54 (Europe PMC)

PMID26512041 (opens in a new tab)PMCIDPMC4624838 (opens in a new tab)DOI10.1136/bmj.h5364 (opens in a new tab)PepBankPUB-26512041
Read at sourcePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on multiple daily insulin injections, liraglutide reduced HbA1c more than placebo at week 24.

    In plain wordsIn adults with type 2 diabetes on multiple daily insulin injections, liraglutide lowered HbA1c more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change from baseline to week 24
    Study

    n = 124

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    HbA1c reduction
    16.9 mmol/mol
    liraglutide
    HbA1c reduction
    4.6 mmol/mol
    placebo
    Between-group difference
    −12.3 mmol/mol
    liraglutide vs placebo

    Source sentences

    Summary
    Liraglutide was associated with a significant reduction of 16.9 mmol/mol (1.5%) in HbA1c versus 4.6 mmol/mol (0.4%) for placebo, difference -12.3 mmol/mol (95% confidence interval -15.8 to -8.8 mmol/mol; -1.13%, -1.45 to -0.81 mmol/mol).
    3 context sentences
    Summary · context
    The main outcome measure was change in HbA1c level from baseline to week 24.
    Summary · context
    The study was a randomised, double blind, placebo controlled trial with a parallel group design carried out at 13 hospital based outpatient clinics and one primary care unit in Sweden.
    Summary · context
    Overall, 124 participants were randomised 1:1 to subcutaneous liraglutide or placebo by minimisation allocation.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on multiple daily insulin injections, liraglutide reduced body weight significantly more than placebo.

    In plain wordsIn adults with type 2 diabetes on multiple daily insulin injections, liraglutide lowered body weight more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change
    Study

    n = 124

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    Body weight reduction
    3.8 kg
    liraglutide
    Body weight reduction
    0 kg
    placebo

    Source sentences

    Summary
    Body weight was significantly reduced in participants in the liraglutide compared with placebo group (3.8 v 0.0 kg, difference -3.8, -4.9 to -2.8 kg)
    2 context sentences
    Summary · context
    The study was a randomised, double blind, placebo controlled trial with a parallel group design carried out at 13 hospital based outpatient clinics and one primary care unit in Sweden.
    Summary · context
    Overall, 124 participants were randomised 1:1 to subcutaneous liraglutide or placebo by minimisation allocation.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on multiple daily insulin injections, total daily insulin doses were reduced significantly more with liraglutide than with placebo.

    In plain wordsIn adults with type 2 diabetes on multiple daily insulin injections, people on liraglutide needed less insulin than people on placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseTotal daily insulin dose
    Study

    n = 124

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    Total daily insulin dose reduction
    18.1 units
    liraglutide
    Total daily insulin dose reduction
    2.3 units
    placebo

    Source sentences

    Summary
    total daily insulin doses were significantly reduced, by 18.1 units and 2.3 units (difference -15.8, -23.1 to -8.5 units).
    2 context sentences
    Summary · context
    The study was a randomised, double blind, placebo controlled trial with a parallel group design carried out at 13 hospital based outpatient clinics and one primary care unit in Sweden.
    Summary · context
    Overall, 124 participants were randomised 1:1 to subcutaneous liraglutide or placebo by minimisation allocation.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on multiple daily insulin injections, the reduction in mean glucose on continuous monitoring was significantly greater with liraglutide than with placebo.

    In plain wordsIn adults with type 2 diabetes on multiple daily insulin injections, average blood sugar on a sensor fell more with liraglutide than with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseMean glucose by continuous glucose monitoring
    Study

    n = 124

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Reductions in mean and standard deviation of glucose levels estimated by masked continuous glucose monitoring were significantly greater in the liraglutide group than placebo group (-1.9 and -0.5 mmol/L).
    2 context sentences
    Summary · context
    The study was a randomised, double blind, placebo controlled trial with a parallel group design carried out at 13 hospital based outpatient clinics and one primary care unit in Sweden.
    Summary · context
    Overall, 124 participants were randomised 1:1 to subcutaneous liraglutide or placebo by minimisation allocation.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on multiple daily insulin injections, the reduction in glucose standard deviation on continuous monitoring was significantly greater with liraglutide than with placebo.

    In plain wordsIn adults with type 2 diabetes on multiple daily insulin injections, blood sugar swings on a sensor fell more with liraglutide than with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseStandard deviation of glucose by continuous glucose monitoring
    Study

    n = 124

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Reductions in mean and standard deviation of glucose levels estimated by masked continuous glucose monitoring were significantly greater in the liraglutide group than placebo group (-1.9 and -0.5 mmol/L).
    2 context sentences
    Summary · context
    The study was a randomised, double blind, placebo controlled trial with a parallel group design carried out at 13 hospital based outpatient clinics and one primary care unit in Sweden.
    Summary · context
    Overall, 124 participants were randomised 1:1 to subcutaneous liraglutide or placebo by minimisation allocation.
  6. 06HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes on multiple daily insulin injections, no severe hypoglycaemic events occurred in either the liraglutide or the placebo group.

    In plain wordsIn adults with type 2 diabetes on multiple daily insulin injections, no one on liraglutide or placebo had a severe low blood sugar event.

    Peptide
    Liraglutide
    Outcome
    No significant changeSevere hypoglycaemic events
    Study

    n = 124

    Comparator
    Placebo
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Neither group experienced severe hypoglycaemic events
    2 context sentences
    Summary · context
    The study was a randomised, double blind, placebo controlled trial with a parallel group design carried out at 13 hospital based outpatient clinics and one primary care unit in Sweden.
    Summary · context
    Overall, 124 participants were randomised 1:1 to subcutaneous liraglutide or placebo by minimisation allocation.
  7. 07HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes on multiple daily insulin injections, non-severe hypoglycaemia did not differ significantly between liraglutide and placebo.

    In plain wordsIn adults with type 2 diabetes on multiple daily insulin injections, milder low blood sugar episodes did not differ between liraglutide and placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeNon-severe hypoglycaemia (symptomatic or asymptomatic)
    Study

    n = 124

    Comparator
    Placebo
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    nor were there any significant differences in symptomatic or asymptomatic non-severe hypoglycaemia (<4.0 or <3.0 mmol/L).
    2 context sentences
    Summary · context
    The study was a randomised, double blind, placebo controlled trial with a parallel group design carried out at 13 hospital based outpatient clinics and one primary care unit in Sweden.
    Summary · context
    Overall, 124 participants were randomised 1:1 to subcutaneous liraglutide or placebo by minimisation allocation.
  8. 08HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes on multiple daily insulin injections, the mean number of non-severe symptomatic hypoglycaemic events was similar with liraglutide and placebo.

    In plain wordsIn adults with type 2 diabetes on multiple daily insulin injections, symptomatic low blood sugar events were equally frequent with liraglutide and placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeMean number of non-severe symptomatic hypoglycaemic events (<4.0 mmol/L)
    Study

    n = 124

    Comparator
    Placebo
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    Mean number of non-severe symptomatic hypoglycaemic events
    1.29 events
    liraglutide
    Mean number of non-severe symptomatic hypoglycaemic events
    1.24 events
    placebo

    Source sentences

    Summary
    The mean number of non-severe symptomatic hypoglycaemic events (<4.0 mmol/L) during follow-up was 1.29 in the liraglutide group and 1.24 in the placebo group (P=0.96).
    2 context sentences
    Summary · context
    The study was a randomised, double blind, placebo controlled trial with a parallel group design carried out at 13 hospital based outpatient clinics and one primary care unit in Sweden.
    Summary · context
    Overall, 124 participants were randomised 1:1 to subcutaneous liraglutide or placebo by minimisation allocation.
  9. 09HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes on multiple daily insulin injections, nausea was more frequent with liraglutide than with placebo.

    In plain wordsIn adults with type 2 diabetes on multiple daily insulin injections, nausea was more common with liraglutide than with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseNausea
    Study

    n = 124

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    Participants with nausea
    32.8%
    liraglutide
    Participants with nausea
    7.8%
    placebo

    Source sentences

    Summary
    Nausea was experienced by 21 (32.8%) participants in the liraglutide group and 5 (7.8%) in the placebo group
    2 context sentences
    Summary · context
    The study was a randomised, double blind, placebo controlled trial with a parallel group design carried out at 13 hospital based outpatient clinics and one primary care unit in Sweden.
    Summary · context
    Overall, 124 participants were randomised 1:1 to subcutaneous liraglutide or placebo by minimisation allocation.
  10. 10HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes on multiple daily insulin injections, similar numbers of participants had a serious adverse event with liraglutide and with placebo.

    In plain wordsIn adults with type 2 diabetes on multiple daily insulin injections, similar numbers had a serious side effect with liraglutide and with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeSerious adverse events
    Study

    n = 124

    Comparator
    Placebo
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    Participants with serious adverse event
    5%
    liraglutide
    Participants with serious adverse event
    7%
    placebo

    Source sentences

    Summary
    3 (5%) and 4 (7%) participants in these groups, respectively, had any serious adverse event.
    2 context sentences
    Summary · context
    The study was a randomised, double blind, placebo controlled trial with a parallel group design carried out at 13 hospital based outpatient clinics and one primary care unit in Sweden.
    Summary · context
    Overall, 124 participants were randomised 1:1 to subcutaneous liraglutide or placebo by minimisation allocation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.